
  
    
      
        Background_NNP
        Influenza_NNP costs_VBZ the_DT US_NNP some_DT 40_CD ,_, 000_CD deaths_NNS ,_, 200_CD ,_, 000_CD
        hospitalizations_NNS ,_, and_CC millions_NNS of_IN workdays_NNS lost_VBD each_DT year_NN ._.
        [_NN 1_CD 2_CD 3_CD ]_NN Most_JJS deaths_NNS (_( 60_CD -_: 90_CD %_NN )_) due_JJ to_TO influenza_NN occur_VB in_IN
        patients_NNS 65_CD years_NNS and_CC older_JJR ,_, but_CC 45_CD -_: 77_CD %_NN of_IN
        influenza-related_JJ hospitalizations_NNS occur_VBP in_IN patients_NNS
        younger_JJR than_IN 65_CD years_NNS old_JJ [_NN 2_CD 4_CD 5_CD ]_NN ._. High_NNP complication_NN
        rates_NNS from_IN influenza_NN in_IN the_DT elderly_JJ have_VBP also_RB been_VBN reported_VBN
        [_NN 6_CD 7_CD ]_NN ._. Little_NNP is_VBZ known_VBN about_IN influenza-related_JJ morbidity_NN
        and_CC health_NN care_NN costs_NNS in_IN younger_JJR populations_NNS and_CC among_IN
        those_DT with_IN preexisting_VBG conditions_NNS such_JJ as_IN diabetes_NN ,_,
        cardiovascular_JJ ,_, or_CC pulmonary_JJ disease_NN ._.
        Diagnosis_NNP of_IN influenza_NN is_VBZ typically_RB based_VBN on_IN the_DT
        presence_NN of_IN symptoms_NNS and_CC the_DT temporal_JJ association_NN with_IN
        known_VBN circulating_VBG virus_NN ._. At_IN the_DT time_NN covered_VBN by_IN this_DT study_NN ,_,
        a_DT rapid_JJ clinic-based_JJ diagnostic_JJ test_NN was_VBD not_RB available_JJ ._.
        Most_JJS research_NN performed_VBN in_IN an_DT observational_NN setting_VBG
        utilizes_NNS clinical_JJ diagnosis_NN and_CC therefore_RB ,_, includes_VBZ both_DT
        influenza_NN and_CC some_DT influenza-like_JJ illnesses_NNS (_( ILI_NNP )_) ._. A_DT
        clinic-based_JJ study_NN inevitably_RB misses_VBZ influenza_NN that_WDT does_VBZ
        not_RB come_VB to_TO clinical_JJ attention_NN ._. This_DT study_NN therefore_RB
        provides_VBZ data_NNS on_IN the_DT burden_NN to_TO the_DT health_NN payor_NN of_IN
        influenza_NN ,_, ILI_NNP ,_, and_CC their_PRP$ related_VBN complications_NNS in_IN a_DT
        population_NN of_IN 2_CD ._. 6_CD million_CD children_NNS and_CC adults_NNS with_IN various_JJ
        risk_NN profiles_NNS ._. The_DT primary_JJ objective_NN of_IN this_DT study_NN was_VBD to_TO
        examine_VB the_DT role_NN of_IN patient_NN characteristics_NNS that_WDT might_MD be_VB
        predictive_JJ of_IN complications_NNS and_CC related_VBN health_NN care_NN costs_NNS
        associated_VBN with_IN influenza_NN and_CC ILI_NNP ._.
      
      
        Methods_NNP
        
          Data_NNP source_NN
          We_PRP used_VBD the_DT automated_VBN claims_NNS database_NN of_IN a_DT large_JJ
          private_JJ New_NNP England_NNP Insurer_NNP (_( NEI_NNP )_) ._. The_DT NEI_NNP database_NN
          contains_VBZ medical_JJ claims_NNS for_IN outpatient_NN and_CC inpatient_NN
          services_NNS and_CC outpatient_NN pharmacy_NN claims_NNS for_IN about_IN
          2_CD ,_, 600_CD ,_, 000_CD residents_NNS of_IN New_NNP England_NNP with_IN comprehensive_JJ
          medical_JJ and_CC prescription_NN drug_NN coverage_NN ._. The_DT number_NN of_IN
          people_NNS over_IN age_NN 65_CD is_VBZ limited_VBN ,_, since_IN Medicare_NNP
          beneficiaries_NNS do_VBP not_RB participate_VB in_IN NEI_NNP ._.
          Each_DT medical_JJ claim_NN contains_VBZ primary_JJ and_CC secondary_JJ
          diagnoses_NNS codes_NNS assigned_VBN using_VBG the_DT International_NNP
          Classification_NNP of_IN Diseases_NNP ,_, ninth_JJ Revision_NNP (_( ICD-_NNP 9_CD )_) [_NN 8_CD ]_NN
          ._. Up_IN to_TO five_CD procedure_NN codes_NNS are_VBP also_RB present_JJ on_IN the_DT
          claim_NN records_NNS and_CC are_VBP coded_VBN using_VBG ICD-_NNP 9_CD ,_, Current_NNP
          Procedural_NNP Terminology_NNP (_( CPT_NNP )_) ,_, or_CC Health_NNP Care_NNP Finance_NNP
          Administration_NNP (_( HCFA_NNP )_) codes_NNS ._. [_NN 8_CD 9_CD 10_CD ]_NN Prescription_NNP
          drugs_NNS dispensed_VBD are_VBP identified_VBN by_IN National_NNP Drug_NNP Code_NNP
          (_( NDC_NNP )_) ,_, American_NNP Hospital_NNP Formulary_NNP Service_NNP (_( AHFS_NNP )_)
          therapeutic_JJ category_NN ,_, brand_NN name_NN ,_, and_CC chemical_NN name_NN [_NN 11_CD
          ]_NN ._. The_DT inpatient_NN transactions_NNS contain_VBP each_DT service_NN the_DT
          provider_NN listed_VBN on_IN the_DT claims_NNS for_IN reimbursement_NN ,_, such_JJ as_IN
          surgeries_NNS ,_, radiologic_JJ tests_NNS ,_, laboratory_NN tests_NNS ,_, room_NN and_CC
          board_NN charges_NNS ,_, or_CC other_JJ specific_JJ cost_NN items_NNS ._. Inpatient_NNP
          pharmacy_NN costs_NNS are_VBP included_VBN in_IN the_DT aggregate_JJ hospital_NN
          charges_NNS ,_, and_CC cannot_NN be_VB separated_JJ out_RP ._. Charges_NNS by_IN the_DT
          provider_NN and_CC amounts_NNS paid_VBN by_IN the_DT insurer_NN ,_, patient_NN ,_, or_CC
          other_JJ third_JJ parties_NNS are_VBP included_VBN ._.
        
        
          Study_NN population_NN
          Patients_NNS with_IN a_DT billed_VBN diagnosis_NN of_IN influenza_NN (_( medical_JJ
          claim_NN with_IN either_DT a_DT primary_JJ or_CC secondary_JJ ICD-_NNP 9_CD diagnosis_NN
          code_NN of_IN 487_CD )_) meeting_VBG the_DT following_VBG criteria_NNS were_VBD
          designated_VBN as_IN having_VBG an_DT influenza_NN /_NN ILI_NNP episode_NN for_IN the_DT
          ensuing_VBG 21_CD days_NNS :_: 1_LS )_) diagnosis_NN occurred_VBD between_IN the_DT
          beginning_NN of_IN October_NNP 1996_CD and_CC the_DT end_NN of_IN April_NNP 1997_CD ;_: 2_LS )_)
          diagnosis_NN did_VBD not_RB occur_VB on_IN the_DT date_NN of_IN a_DT immunization_NN for_IN
          influenza_NN ;_: 3_LS )_) diagnosis_NN was_VBD preceded_VBN by_IN at_IN least_JJS one_CD year_NN
          of_IN continuous_JJ health_NN insurance_NN coverage_NN ,_, with_IN no_DT gaps_NNS in_IN
          coverage_NN that_WDT exceeded_VBD 30_CD days_NNS ;_: and_CC 4_LS )_) insurance_NN coverage_NN
          during_IN the_DT 21_CD -_: day_NN follow_VB up_RB period_NN was_VBD continuous_JJ ._. We_PRP
          will_MD use_VB the_DT term_NN "_'' interval_NN of_IN care_NN "_'' interchangeably_RB with_IN
          "_'' episode_NN "_'' to_TO describe_VB this_DT period_NN ._. Multiple_NNP claims_VBZ for_IN
          care_NN of_IN influenza_NN for_IN the_DT same_JJ patient_NN occurring_VBG within_IN
          the_DT 21_CD -_: day_NN follow-up_JJ period_NN were_VBD taken_VBN to_TO be_VB part_NN of_IN a_DT
          single_JJ episode_NN ._. We_PRP refer_VBP to_TO the_DT qualifying_VBG influenza_NN
          diagnosis_NN day_NN and_CC the_DT subsequent_JJ 21_CD -_: day_NN follow-up_JJ period_NN
          as_IN the_DT interval_NN of_IN care_NN throughout_IN this_DT report_NN ._. The_DT
          21_CD -_: day_NN period_NN captures_NNS the_DT longest_JJS likely_JJ duration_NN of_IN
          symptoms_NNS directly_RB caused_VBN by_IN the_DT influenza_NN infection_NN (_( 7_CD -_: 10_CD
          days_NNS )_) plus_CC a_DT period_NN to_TO account_VB for_IN the_DT evolution_NN and_CC
          resolution_NN of_IN complications_NNS of_IN the_DT infection_NN ._. While_IN a_DT
          rare_JJ ,_, serious_JJ complication_NN could_MD lead_VB to_TO a_DT protracted_JJ
          illness_NN ,_, we_PRP felt_VBD that_IN the_DT problem_NN of_IN resolving_VBG the_DT
          relative_JJ contributions_NNS of_IN underlying_VBG and_CC acute_JJ disease_NN in_IN
          these_DT settings_NNS would_MD introduce_VB substantial_JJ error_NN ,_, and_CC
          provide_VB relatively_RB little_RB additional_JJ information_NN ._. We_PRP will_MD
          use_VB the_DT term_NN "_'' influenza_NN /_NN ILI_NNP "_'' throughout_IN this_DT manuscript_NN
          recognizing_VBG that_IN medical_JJ claims_NNS with_IN an_DT ICD-_NNP 9_CD code_NN of_IN 487_CD
          include_VBP influenza_NN as_RB well_RB as_IN some_DT cases_NNS of_IN ILI_NNP ._.
        
        
          Characteristics_NNP of_IN influenza_NN /_NN ILI-related_NNP
          episodes_NNS
          We_PRP characterized_VBD each_DT influenza_NN /_NN ILI_NNP episode_NN according_VBG
          to_TO :_: (_( 1_LS )_) age_NN at_IN time_NN of_IN influenza_NN /_NN ILI_NNP diagnosis_NN ;_: (_( 2_LS )_)
          gender_NN ;_: (_( 3_LS )_) recorded_VBN influenza_NN immunization_NN status_NN ;_: (_( 4_LS )_)
          prior_RB influenza_NN /_NN ILI_NNP episodes_NNS during_IN the_DT study_NN period_NN ;_: (_( 5_LS )_)
          antiviral_JJ influenza_NN treatment_NN (_( amantadine_NN or_CC
          rimantadine_NN )_) ;_: (_( 6_CD )_) total_JJ patient_NN health_NN care_NN costs_NNS in_IN the_DT
          three_CD months_NNS before_IN influenza_NN /_NN ILI_NNP diagnosis_NN )_) ;_: (_( 7_CD )_)
          co-morbidities_JJ for_IN which_WDT health_NN services_NNS were_VBD received_VBN in_IN
          (_( a_DT )_) the_DT 30_CD days_NNS and_CC (_( b_SYM )_) the_DT year_NN before_IN influenza_NN /_NN ILI_NNP
          diagnosis_NN (_( chronic_JJ lung_NN disease_NN ,_, chronic_JJ renal_JJ disease_NN ,_,
          diabetes_NN ,_, malignancies_NNS ,_, HIV_NNP infections_NNS ,_, and_CC chronic_JJ heart_NN
          disease_NN )_) ;_: (_( 8_CD )_) immunosuppressive_JJ and_CC chronic_JJ
          corticosteroid_NN drug_NN use_NN during_IN the_DT year_NN before_IN
          influenza_NN /_NN ILI_NNP diagnosis_NN ;_: (_( 9_CD )_) health_NN services_NNS in_IN the_DT 30_CD
          days_NNS before_IN influenza_NN /_NN ILI_NNP diagnosis_NN for_IN conditions_NNS that_WDT
          would_MD have_VB been_VBN characterized_VBN as_IN complications_NNS or_CC
          manifestations_NNS had_VBD they_PRP occurred_VBD during_IN the_DT influenza_NN /_NN ILI_NNP
          episode_NN (_( see_VB below_IN )_) ._. The_DT 30_CD -_: day_NN window_NN was_VBD chosen_VBN on_IN
          clinical_JJ grounds_NNS to_TO capture_VB medical_JJ conditions_NNS that_WDT were_VBD
          unstable_JJ ,_, and_CC the_DT one-year_JJ window_NN was_VBD intended_VBN to_TO capture_VB
          all_DT active_JJ medical_JJ conditions_NNS ._. Inevitably_RB ,_, some_DT routine_JJ
          care_NN will_MD have_VB occurred_VBN in_IN the_DT 30_CD -_: day_NN window_NN ,_, and_CC some_DT
          conditions_NNS treated_VBN in_IN the_DT past_JJ year_NN will_MD not_RB have_VB been_VBN
          active_JJ at_IN the_DT time_NN of_IN the_DT influenza_NN episode_NN ._.
          We_PRP evaluated_VBD influenza_NN immunizations_NNS between_IN September_NNP
          1_CD ,_, 1996_CD and_CC the_DT day_NN before_IN the_DT initial_JJ influenza_NN /_NN ILI_NNP
          diagnosis_NN ._. Antiviral_NNP influenza_NN medications_NNS dispensed_VBD
          within_IN the_DT three_CD days_NNS before_RB ,_, the_DT day_NN of_IN ,_, or_CC the_DT three_CD
          days_NNS after_IN the_DT initial_JJ influenza_NN /_NN ILI_NNP diagnosis_NN date_NN were_VBD
          noted_VBN ._. We_PRP created_VBD this_DT seven-day_JJ time_NN window_NN to_TO account_VB
          for_IN prescriptions_NNS that_WDT may_MD have_VB been_VBN dispensed_VBD for_IN the_DT
          current_JJ diagnosis_NN before_IN an_DT office_NN visit_NN (_( e_SYM ._. g_SYM ._. ,_, by_IN
          telephoned_VBD prescription_NN )_) or_CC within_IN a_DT few_JJ days_NNS after_IN an_DT
          office_NN visit_NN ._. We_PRP categorized_VBN health_NN care_NN costs_NNS in_IN the_DT
          three_CD months_NNS before_IN the_DT influenza_NN /_NN ILI_NNP diagnosis_NN in_IN
          quintile_NN ranges_NNS as_IN follows_VBZ :_: (_( 1_LS )_) $_$ 0_CD ,_, (_( 2_LS )_) up_IN to_TO $_$ 87_CD ,_, (_( 3_LS )_)
          $_$ 87_CD -_: $_$ 200_CD ,_, (_( 4_LS )_) $_$ 200_CD -_: $_$ 453_CD and_CC (_( 5_LS )_) $_$ 453_CD and_CC above_IN ._. The_DT
          mean_NN and_CC median_JJ three-month_JJ costs_NNS preceding_VBG influenza_NN /_NN ILI_NNP
          diagnoses_NNS was_VBD $_$ 644_CD and_CC $_$ 135_CD ,_, respectively_RB ._. The_DT underlying_VBG
          co-morbid_JJ conditions_NNS we_PRP considered_VBD included_VBD chronic_JJ lung_NN
          disease_NN ,_, chronic_JJ renal_JJ disease_NN ,_, diabetes_NN ,_, malignancies_NNS ,_,
          HIV_NNP infections_NNS ,_, chronic_JJ heart_NN disease_NN ,_, and_CC chronic_JJ renal_JJ
          disease_NN ._.
        
        
          Complications_NNP and_CC manifestations_NNS of_IN
          influenza_NN /_NN ILI_NNP
          We_PRP defined_VBD complications_NNS and_CC manifestations_NNS occurring_VBG
          on_IN the_DT day_NN of_IN the_DT influenza_NN /_NN ILI_NNP diagnosis_NN or_CC during_IN the_DT
          21_CD -_: day_NN follow-up_JJ period_NN using_VBG individual_JJ or_CC combinations_NNS
          of_IN ICD-_NNP 9_CD codes_NNS to_TO capture_VB respiratory_JJ ,_, cardiovascular_JJ ,_,
          infectious_JJ ,_, musculoskeletal_NN ,_, symptoms_NNS ,_, and_CC other_JJ
          diseases_NNS ._. Ambulatory_NNP care_NN visits_NNS ,_, hospitalizations_NNS ,_,
          procedures_NNS ,_, and_CC emergency_NN room_NN visits_NNS were_VBD included_VBN ._.
          Throughout_IN this_DT report_NN ,_, these_DT are_VBP referred_VBN to_TO as_IN
          complications_NNS of_IN influenza_NN /_NN ILI_NNP ._. Please_VB see_VB Additional_JJ
          File_NNP [_NN Appendix_NNP A_DT ._. doc_NN ]_NN for_IN specific_JJ ICD_NNP 9_CD codes_NNS ._.
        
        
          Comorbidities_NNP
          We_PRP identified_VBD the_DT presence_NN of_IN chronic_JJ lung_NN disease_NN ,_,
          chronic_JJ renal_JJ disease_NN ,_, diabetes_NN ,_, malignancies_NNS ,_, HIV_NNP
          infections_NNS ,_, and_CC chronic_JJ heart_NN disease_NN using_VBG algorithms_NNS
          based_VBN on_IN health_NN services_NNS utilization_NN ,_, detailed_JJ in_IN
          Additional_JJ File_NNP [_NN Appendix_NNP B_NNP ._. doc_NN ]_NN ._.
        
        
          Hospitalizations_NNP
          Influenza_NNP /_NN ILI-related_NNP hospitalizations_NNS were_VBD defined_VBN
          using_VBG the_DT ICD-_NNP 9_CD diagnoses_NNS codes_NNS recorded_VBN on_IN the_DT detailed_VBN
          inpatient_NN claims_NNS ,_, categorized_VBN as_IN listed_VBN above_IN ._. We_PRP
          calculated_VBD mean_VB and_CC median_JJ length_NN of_IN stay_NN in_IN hospital_NN ._.
          There_EX were_VBD 10_CD (_( out_IN of_IN 115_CD )_) hospitalizations_NNS that_WDT
          continued_VBD beyond_IN the_DT 21_CD -_: day_NN follow-up_JJ period_NN ._. For_IN the_DT
          complications_NNS analysis_NN ,_, these_DT counted_VBN in_IN exactly_RB the_DT same_JJ
          manner_NN as_IN the_DT 105_CD hospitalizations_NNS that_WDT were_VBD completed_VBN
          within_IN the_DT 21_CD -_: day_NN follow-up_JJ ._. For_IN the_DT primary_JJ cost_NN and_CC
          duration_NN of_IN stay_NN analyses_NNS data_NNS from_IN the_DT 10_CD extended_VBN
          hospitalizations_NNS were_VBD retained_VBN only_RB for_IN hospitalized_VBN days_NNS
          in_IN the_DT follow-up_JJ period_NN ,_, as_IN an_DT approximate_JJ way_NN of_IN
          partitioning_VBG costs_NNS for_IN events_NNS with_IN mulitfactorial_NN
          etiology_NN ._. Total_JJ hospital_NN cost_NN was_VBD multiplied_VBN by_IN the_DT
          proportion_NN of_IN hospital_NN days_NNS that_WDT fell_VBD within_IN the_DT
          follow-up_JJ period_NN ._. We_PRP also_RB present_VB the_DT total_JJ cost_NN and_CC
          length_NN of_IN stay_NN without_IN truncation_NN ._.
        
        
          Health_NN care_NN costs_NNS
          We_PRP characterized_VBD each_DT influenza_NN /_NN ILI_NNP interval_NN of_IN care_NN
          by_IN total_JJ cost_NN and_CC influenza_NN /_NN ILI-related_NNP cost_NN ._. We_PRP defined_VBD
          influenza_NN /_NN ILI-related_NNP costs_NNS as_IN those_DT associated_VBN with_IN
          ongoing_JJ care_NN for_IN influenza_NN /_NN ILI_NNP and_CC with_IN complications_NNS of_IN
          influenza_NN /_NN ILI_NNP ,_, including_VBG medication_NN costs_NNS ,_, which_WDT occurred_VBD
          during_IN the_DT influenza_NN /_NN ILI_NNP interval_NN of_IN care_NN (_( see_VB above_IN list_NN
          of_IN ICD-_NNP 9_CD codes_NNS )_) ._. Influenza_NNP /_NN ILI-related_NNP medications_NNS were_VBD
          those_DT commonly_RB prescribed_VBN for_IN influenza_NN /_NN ILI_NNP symptoms_NNS ,_,
          manifestations_NNS and_CC complications_NNS (_( oral_JJ ,_, injectable_JJ ,_,
          ophthalmic_JJ and_CC topical_JJ antibiotics_NNS ;_: antitussives_NNS ;_:
          expectorants_NNS ,_, and_CC mucolytic_JJ agents_NNS ;_:
          decongestants_NNS ;_: aspirin_NN ,_, acetaminophen_NN ,_, ibuprofen_NN ,_,
          naproxen_NN ;_: amantadine_NN ,_, rimantadine_NN ;_: beta-agonists_JJ ;_:
          theophylline_NN ;_: oral_JJ ,_, injectable_JJ ,_, rectal_NN or_CC inhaled_JJ
          steroids_NNS ;_: ipratropium_NN and_CC cromolyn_NN sodium_NN )_) ._.
          We_PRP defined_VBD total_JJ costs_NNS as_IN the_DT sum_NN of_IN total_JJ health_NN care_NN
          costs_NNS for_IN all_DT services_NNS incurred_VBN during_IN the_DT interval_NN of_IN
          care_NN ._. Costs_NNS presented_VBN in_IN this_DT report_NN were_VBD the_DT sum_NN of_IN the_DT
          amount_NN paid_VBN by_IN the_DT insurer_NN and_CC the_DT patient_NN ._. Patient_NNP costs_NNS
          include_VBP a_DT patient_NN 's_POS deductible_JJ ,_, co-payment_JJ ,_, coinsurance_NN ,_,
          and_CC coordination_NN of_IN benefit_NN amounts_NNS ._. Societal_NNP costs_NNS and_CC
          patient_NN level_NN costs_NNS such_JJ as_IN lost_VBN workdays_NNS were_VBD not_RB
          considered_VBN ._.
        
        
          Analysis_NNP
          We_PRP used_VBD logistic_JJ regression_NN modeling_NN to_TO examine_VB the_DT
          association_NN of_IN potential_JJ predictive_JJ factors_NNS with_IN
          influenza_NN /_NN ILI-related_NNP complications_NNS and_CC hospitalizations_NNS ._.
          These_DT models_NNS permitted_VBD adjustment_NN for_IN all_DT of_IN the_DT possible_JJ
          predictive_JJ factors_NNS concurrently_RB ;_: no_DT variables_NNS were_VBD
          dropped_VBN from_IN the_DT models_NNS ._.
        
      
      
        Results_NNS
        
          Study_NN population_NN and_CC intervals_NNS of_IN care_NN
          6_CD ,_, 269_CD persons_NNS met_VBD eligibility_NN and_CC enrollment_NN criteria_NNS ;_:
          they_PRP experienced_VBD 6_CD ,_, 660_CD intervals_NNS of_IN influenza_NN /_NN ILI_NNP care_NN ._.
          Thirty_NNP intervals_NNS of_IN care_NN were_VBD excluded_VBN from_IN the_DT analysis_NN
          because_IN they_PRP occurred_VBD in_IN subgroups_NNS with_IN very_RB small_JJ
          numbers_NNS of_IN patients_NNS ,_, within_IN which_WDT it_PRP would_MD have_VB been_VBN
          impossible_JJ to_TO obtain_VB stable_JJ disease-specific_JJ estimates_NNS
          (_( HIV_NNP (_( 4_CD men_NNS ;_: 2_CD women_NNS )_) ;_: chronic_JJ renal_JJ disease_NN (_( 5_CD men_NNS ;_: 7_CD
          women_NNS )_) and_CC immunosuppressive_JJ therapy_NN (_( 3_CD men_NNS ;_: 10_CD women_NNS )_) )_) ._.
          The_DT remaining_VBG 6_CD ,_, 630_CD influenza_NN /_NN ILI_NNP intervals_NNS of_IN care_NN
          (_( 6_CD ,_, 241_CD patients_NNS )_) formed_VBD the_DT basis_NN of_IN this_DT analysis_NN ._.
          Ninety-four_NNP percent_NN of_IN patients_NNS (_( 5_CD ,_, 895_CD )_) had_VBD a_DT single_JJ
          episode_NN ._. Approximately_RB 5_CD %_NN (_( 308_CD )_) experienced_VBN two_CD episodes_NNS
          and_CC 1_CD %_NN (_( 30_CD )_) had_VBD three_CD or_CC more_JJR during_IN the_DT study_NN period_NN ._. In_IN
          94_CD %_NN of_IN the_DT intervals_NNS of_IN care_NN ,_, influenza_NN /_NN ILI_NNP was_VBD diagnosed_VBN
          in_IN an_DT outpatient_NN setting_VBG ._. Approximately_RB 5_CD %_NN were_VBD diagnosed_VBN
          in_IN the_DT emergency_NN room_NN and_CC 1_CD %_NN were_VBD diagnosed_VBN upon_IN
          hospitalization_NN ._.
          Approximately_RB 38_CD %_NN of_IN episodes_NNS included_VBD outpatient_NN
          procedures_NNS or_CC services_NNS associated_VBN with_IN influenza_NN /_NN ILI_NNP or_CC
          complications_NNS ._. Outpatient_NNP dispensings_NNS were_VBD recorded_VBN for_IN
          50_CD %_NN of_IN the_DT episodes_NNS for_IN the_DT medications_NNS commonly_RB
          prescribed_VBN for_IN influenza_NN /_NN ILI_NNP symptoms_NNS ,_, manifestations_NNS ,_,
          and_CC complications_NNS on_IN the_DT day_NN of_IN or_CC during_IN the_DT 21_CD days_NNS
          beyond_IN their_PRP$ diagnosis_NN ._. Antibiotics_NNP were_VBD prescribed_VBN for_IN
          39_CD %_NN of_IN the_DT episodes_NNS ._. Four_CD percent_NN of_IN the_DT episodes_NNS had_VBD
          dispensings_NNS of_IN antivirals_NNS (_( amantadine_NN or_CC
          rimantadine_NN )_) ._.
          Overall_RB ,_, 23_CD %_NN of_IN the_DT influenza_NN /_NN ILI_NNP episodes_NNS had_VBD
          evidence_NN of_IN one_CD or_CC more_RBR co-morbid_JJ conditions_NNS occurring_VBG in_IN
          the_DT year_NN before_IN the_DT influenza_NN /_NN ILI_NNP diagnosis_NN ._. Chronic_NNP lung_NN
          disease_NN was_VBD the_DT most_RBS prevalent_JJ ,_, observed_VBD for_IN
          approximately_RB 20_CD %_NN of_IN the_DT influenza_NN /_NN ILI_NNP episodes_NNS ,_, at_IN every_DT
          age_NN ._. Chronic_NNP corticosteroid_NN use_NN ,_, malignancy_NN ,_, chronic_JJ
          heart_NN disease_NN ,_, and_CC diabetes_NN became_VBD more_RBR common_JJ with_IN
          advancing_VBG age_NN ._. In_IN approximately_RB 2_CD %_NN of_IN the_DT influenza_NN /_NN ILI_NNP
          intervals_NNS of_IN care_NN ,_, patients_NNS had_VBD evidence_NN of_IN multiple_JJ
          co-morbidities_JJ and_CC this_DT rose_VBD with_IN higher_JJR age_NN groups_NNS ,_,
          reaching_VBG 21_CD %_NN for_IN males_NNS age_VBP 65_CD +_NN and_CC 17_CD %_NN for_IN females_NNS age_VBP
          65_CD +_NN ._. (_( Table_NNP 1_LS )_) ._.
        
        
          Influenza_NNP /_NN ILI-related_NNP complications_NNS and_CC
          hospitalizations_NNS
          Overall_RB ,_, 23_CD %_NN of_IN intervals_NNS of_IN care_NN had_VBD an_DT
          influenza_NN /_NN ILI-related_NNP complication_NN ._. Respiratory_JJ
          complications_NNS were_VBD the_DT most_RBS common_JJ (_( 13_CD %_NN )_) ._. Approximately_RB
          2_CD %_NN of_IN influenza_NN /_NN ILI_NNP intervals_NNS of_IN care_NN resulted_VBD in_IN a_DT
          hospitalization_NN for_IN influenza_NN /_NN ILI-related_NNP complications_NNS ._.
          Four_CD percent_NN resulted_VBD in_IN an_DT emergency_NN room_NN visit_NN and_CC 20_CD %_NN
          resulted_VBD in_IN an_DT office_NN visit_NN (_( data_NNS not_RB shown_VBN )_) ._.
          The_DT median_JJ and_CC mean_VB length_NN of_IN hospital_NN stay_NN during_IN the_DT
          observation_NN period_NN for_IN influenza_NN /_NN ILI-related_NNP
          complications_NNS was_VBD 5_CD days_NNS ._. Including_VBG portions_NNS of_IN
          hospitalizations_NNS that_WDT extended_VBD outside_IN of_IN the_DT 21_CD -_: day_NN
          observation_NN period_NN ,_, the_DT median_JJ length_NN of_IN stay_NN in_IN hospital_NN
          was_VBD still_RB five_CD days_NNS ._. The_DT mean_NN was_VBD 8_CD ._. 4_CD days_NNS ._.
          Table_NNP 2_CD shows_VBZ the_DT unadjusted_JJ associations_NNS for_IN the_DT
          potential_JJ predictors_NNS of_IN influenza_NN /_NN ILI-related_NNP
          hospitalizations_NNS and_CC complications_NNS during_IN the_DT
          influenza_NN /_NN ILI_NNP intervals_NNS of_IN care_NN ._. In_IN general_JJ ,_, the_DT patterns_NNS
          seen_VBN for_IN factors_NNS associated_VBN with_IN hospitalizations_NNS were_VBD
          similar_JJ to_TO those_DT seen_VBN for_IN influenza_NN /_NN ILI-related_NNP
          complications_NNS ._. Older_JJR age_NN ,_, prior_RB immunization_NN ,_, recent_JJ
          complications_NNS or_CC co-morbid_JJ diagnoses_NNS (_( 30_CD days_NNS before_IN the_DT
          influenza_NN /_NN ILI_NNP diagnosis_NN )_) ,_, co-morbidities_JJ identified_VBN in_IN
          the_DT year_NN prior_RB to_TO diagnosis_NN ,_, and_CC high_JJ recent_JJ health_NN care_NN
          costs_NNS (_( in_IN the_DT previous_JJ three_CD months_NNS )_) were_VBD all_DT strongly_RB
          associated_VBN with_IN hospitalizations_NNS or_CC complications_NNS of_IN
          influenza_NN /_NN ILI_NNP ._.
          Table_NNP 3_CD presents_VBZ the_DT results_NNS from_IN the_DT logistic_JJ
          regression_NN analyses_NNS for_IN predictors_NNS of_IN any_DT type_NN of_IN
          influenza_NN /_NN ILI-related_NNP complication_NN and_CC hospitalization_NN ._.
          Adults_NNS in_IN the_DT oldest_JJS age_NN groups_NNS (_( 55_CD -_: 64_CD and_CC 65_CD +_NN )_) were_VBD
          nearly_RB twice_RB as_IN likely_JJ to_TO be_VB hospitalized_VBN (_( 55_CD -_: 64_CD OR_NNP =_SYM
          1_CD ._. 75_CD ;_: 95_CD %_NN CI_NNP =_SYM 0_CD ._. 87_CD -_: 3_CD ._. 52_CD ;_: 65_CD +_NN OR_NNP =_SYM 1_CD ._. 93_CD ;_: 95_CD %_NN CI_NNP =_SYM
          0_CD ._. 82_CD -_: 4_CD ._. 56_CD )_) ,_, as_IN were_VBD those_DT in_IN the_DT 35_CD -_: 44_CD year_NN old_JJ group_NN ._.
          Patients_NNS with_IN a_DT recorded_VBN immunization_NN were_VBD over_IN 2_CD ._. 17_CD
          times_NNS as_IN likely_JJ (_( 95_CD %_NN CI_NNP 1_CD ._. 06_CD -_: 4_CD ._. 43_CD )_) to_TO be_VB hospitalized_VBN
          than_IN patients_NNS without_IN evidence_NN of_IN immunization_NN ._. Intervals_NNP
          of_IN care_NN with_IN recent_JJ influenza_NN /_NN ILI-related_NNP complications_NNS
          or_CC co-morbid_JJ diagnoses_NNS (_( within_IN 30_CD days_NNS )_) were_VBD 3_CD ._. 2_CD times_NNS
          (_( 95_CD %_NN CI_NNP 1_CD ._. 96_CD -_: 5_CD ._. 13_CD )_) more_RBR likely_JJ to_TO be_VB hospitalized_VBN
          compared_VBN to_TO those_DT without_IN a_DT recent_JJ concurrent_JJ
          complication_NN ._. Episodes_NNP with_IN the_DT highest_JJS quintile_NN of_IN
          medical_JJ care_NN costs_NNS in_IN the_DT preceding_VBG three_CD months_NNS had_VBD
          about_IN a_DT 1_CD ._. 7_CD -_: fold_VB increased_VBN likelihood_NN of_IN being_VBG
          hospitalized_VBN (_( 95_CD %_NN CI_NNP 0_CD ._. 77_CD -_: 3_CD ._. 84_CD )_) ._. Prevalent_NNP co-morbid_JJ
          conditions_NNS and_CC medication_NN use_NN were_VBD generally_RB associated_VBN
          with_IN an_DT increased_VBN likelihood_NN of_IN hospitalization_NN ._.
          The_DT logistic_JJ models_NNS for_IN possible_JJ predictors_NNS of_IN
          influenza_NN /_NN ILI-related_NNP complications_NNS showed_VBD that_IN children_NNS
          under_IN the_DT age_NN of_IN five_CD years_NNS (_( OR_NNP =_SYM 1_CD ._. 55_CD ;_: 95_CD %_NN CI_NNP =_SYM
          1_CD ._. 26_CD -_: 1_CD ._. 91_CD )_) and_CC adults_NNS over_IN the_DT age_NN of_IN 65_CD years_NNS were_VBD more_RBR
          likely_JJ (_( OR_NNP =_SYM 1_CD ._. 54_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 06_CD -_: 2_CD ._. 24_CD )_) to_TO experience_VB
          complications_NNS when_WRB compared_VBN to_TO the_DT 35_CD -_: 44_CD age_NN group_NN ._.
          Intervals_NNP of_IN care_NN for_IN wpatients_NNS diagnosed_VBN with_IN recent_JJ
          influenza_NN /_NN ILI-related_NNP complications_NNS or_CC co-morbid_JJ
          diagnosis_NN (_( 30_CD days_NNS prior_RB )_) were_VBD more_RBR likely_JJ (_( OR_NNP =_SYM 1_CD ._. 47_CD ;_:
          95_CD %_NN CI_NNP 1_CD ._. 27_CD -_: 1_CD ._. 70_CD )_) to_TO result_VB in_IN patients_NNS having_VBG
          influenza_NN /_NN ILI-related_NNP complications_NNS ._. Higher_JJR quintiles_NNS for_IN
          cost_NN of_IN medical_JJ services_NNS received_VBD in_IN the_DT 3_CD -_: month_NN period_NN
          preceding_VBG the_DT influenza_NN /_NN ILI_NNP diagnosis_NN were_VBD more_RBR strongly_RB
          associated_VBN with_IN complications_NNS of_IN influenza_NN /_NN ILI_NNP (_( 4_CD
          thquintile_NN OR_NNP =_SYM 1_CD ._. 21_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 00_CD -_: 1_CD ._. 47_CD ;_: 5_CD thquintile_NN OR_NNP
          =_SYM 1_CD ._. 56_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 28_CD -_: 1_CD ._. 91_CD )_) ._. Prevalent_NNP co-morbidities_JJ
          such_JJ as_IN maligna_NN (_( 95_CD %_NN CI_NNP =_SYM 1_CD ._. 19_CD -_: 2_CD ._. 61_CD )_) and_CC diabetes_NN (_( OR_NNP =_SYM
          1_CD ._. 74_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 16_CD -_: 2_CD ._. 61_CD )_) were_VBD significantly_RB related_VBN to_TO
          the_DT occurrence_NN of_IN influenza_NN /_NN ILI-related_NNP complications_NNS
          during_IN intervals_NNS of_IN care_NN for_IN influenza_NN /_NN ILI_NNP ._. (_( Table_NNP 3_LS )_)
          Table_NNP 4_CD shows_VBZ the_DT total_NN ,_, mean_VB and_CC median_JJ costs_NNS incurred_VBN
          on_IN influenza_NN /_NN ILI_NNP diagnosis_NN date_NN and_CC during_IN the_DT 21_CD -_: day_NN
          follow-up_JJ period_NN ,_, stratified_JJ by_IN possible_JJ predictor_NN
          variables_NNS ._. Intervals_NNP of_IN care_NN for_IN patients_NNS with_IN prevalent_JJ
          co-morbid_JJ conditions_NNS had_VBD a_DT consistently_RB higher_JJR median_JJ
          influenza_NN /_NN ILI-related_NNP costs_NNS compared_VBN to_TO those_DT without_IN
          co-morbidities_JJ ._. Influenza_NNP /_NN ILI-related_NNP costs_NNS accounted_VBD for_IN
          76_CD %_NN of_IN the_DT total_JJ health_NN care_NN costs_NNS incurred_VBN during_IN the_DT
          interval_NN of_IN care_NN (_( $_$ 1_CD ,_, 981_CD ,_, 072_CD /_NN $_$ 2_CD ,_, 622_CD ,_, 179_CD )_) ._.
        
      
      
        Discussion_NNP
        Elderly_JJ patients_NNS and_CC patients_NNS with_IN an_DT underlying_VBG chronic_JJ
        illness_NN ,_, a_DT recent_JJ complication_NN ,_, or_CC a_DT higher_JJR health_NN care_NN
        cost_NN in_IN the_DT recent_JJ months_NNS were_VBD at_IN the_DT highest_JJS risk_NN of_IN
        hospitalization_NN and_CC complications_NNS after_IN a_DT diagnosis_NN of_IN
        influenza_NN /_NN ILI_NNP ._. Influenza_NNP /_NN ILI-related_NNP health_NN care_NN costs_NNS
        represented_VBD the_DT bulk_NN of_IN total_JJ health_NN care_NN costs_NNS during_IN an_DT
        influenza_NN /_NN ILI_NNP interval_NN of_IN care_NN ._. In_IN addition_NN to_TO a_DT
        confirmation_NN of_IN what_WP we_PRP would_MD expect_VB qualitatively_RB for_IN the_DT
        healthcare_NN burden_NN of_IN influenza_NN ,_, our_PRP$ observation_NN provides_VBZ a_DT
        useful_JJ quantitative_JJ estimate_NN for_IN these_DT effects_NNS in_IN the_DT
        general_JJ population_NN ._.
        The_DT diagnosis_NN of_IN influenza_NN /_NN ILI_NNP was_VBD based_VBN on_IN ICD-_NNP 9_CD codes_NNS
        and_CC did_VBD not_RB incorporate_VB viral_JJ isolates_VBZ or_CC laboratory_NN
        confirmation_NN ._. "_'' Influenza_NNP /_NN ILI_NNP "_'' in_IN this_DT study_NN is_VBZ likely_JJ to_TO be_VB
        representative_NN ,_, on_IN a_DT population_NN level_NN ,_, of_IN influenza_NN /_NN ILI_NNP
        diagnoses_NNS and_CC a_DT smaller_JJR percentage_NN of_IN more_JJR severe_JJ
        influenza-like_JJ illness_NN ._. The_DT 21_CD -_: day_NN follow-up_JJ period_NN
        incorporated_VBD a_DT clinical_JJ expectation_NN that_IN the_DT vast_JJ majority_NN
        of_IN influenza_NN /_NN ILI-related_NNP complications_NNS would_MD occur_VB within_IN
        this_DT period_NN ,_, and_CC that_IN complications_NNS that_WDT extended_VBD beyond_IN 21_CD
        days_NNS would_MD usually_RB be_VB ascribable_JJ in_IN part_NN to_TO pre-existing_JJ
        illness_NN ._. More_JJR sophisticate_NN approaches_NNS are_VBP imaginable_JJ ,_, but_CC
        not_RB among_IN multiple_JJ causes_NNS ,_, which_WDT in_IN any_DT case_NN would_MD have_VB
        been_VBN impossible_JJ to_TO implement_VB at_IN the_DT level_NN of_IN insurance_NN
        claims_NNS analysis_NN ._.
        This_DT study_NN found_VBD that_IN patients_NNS with_IN a_DT record_NN of_IN an_DT
        influenza_NN immunization_NN were_VBD at_IN a_DT higher_JJR risk_NN for_IN
        hospitalization_NN than_IN those_DT who_WP were_VBD not_RB vaccinated_JJ ._. This_DT is_VBZ
        clearly_RB not_RB a_DT vaccine_NN effect_NN ,_, but_CC instead_RB an_DT effect_NN
        attributable_JJ to_TO the_DT kinds_NNS of_IN patients_NNS in_IN the_DT United_NNP States_NNPS
        who_WP typically_RB received_VBD influenza_NN vaccination_NN in_IN a_DT doctor_NN 's_POS
        office_NN during_IN the_DT period_NN of_IN the_DT study_NN ._. Vaccine_NNP is_VBZ indicated_VBN
        for_IN patients_NNS at_IN high_JJ risk_NN of_IN complications_NNS ,_, and_CC that_DT risk_NN
        applies_VBZ just_RB as_IN much_JJ to_TO ILI_NNP ,_, which_WDT presumably_RB account_NN for_IN
        the_DT great_JJ majority_NN of_IN events_NNS among_IN vaccinated_JJ persons_NNS ._.
        Antiviral_NNP use_NN was_VBD not_RB extensive_JJ ,_, and_CC the_DT current_JJ study_NN
        dates_NNS preceded_VBN the_DT introduction_NN of_IN zanamivir_NN and_CC
        oseltamivir_NN ._. It_PRP appears_VBZ that_DT zanamivir_NN reduces_VBZ the_DT risk_NN of_IN
        complication_NN in_IN high-risk_JJ patients_NNS ._. [_NN 12_CD ]_NN We_PRP found_VBD some_DT
        indication_NN (_( although_IN not_RB statistically_RB significant_JJ )_) that_DT
        use_NN of_IN amantadine_NN and_CC rimantadine_NN may_MD have_VB prevented_VBN
        hospitalizations_NNS (_( OR_NNP =_SYM 0_CD ._. 6_CD )_) and_CC substantially_RB reduced_VBN
        costs_NNS ._.
        Influenza_NNP /_NN ILI_NNP adversely_RB affects_VBZ individuals_NNS with_IN a_DT
        variety_NN of_IN chronic_JJ underlying_VBG conditions_NNS ,_, supporting_VBG the_DT
        Center_NNP for_IN Disease_NNP Control_NNP and_CC Prevention_NNP Immunization_NNP
        recommendations_NNS for_IN influenza_NN immunization_NN [_NN 15_CD ]_NN ._. Unlike_IN
        other_JJ studies_NNS that_WDT have_VBP evaluated_VBN the_DT cost-effectiveness_JJ of_IN
        influenza_NN immunization_NN [_NN 13_CD 14_CD 15_CD 16_CD ]_NN ,_, our_PRP$ data_NNS quantify_VB
        a_DT major_JJ cost_NN impact_NN of_IN ILI_NNP and_CC influenza_NN /_NN ILI_NNP in_IN a_DT large_JJ
        population_NN (_( over_IN 6200_CD patients_NNS )_) with_IN wide-variation_JJ in_IN ages_NNS
        and_CC health_NN status_NN ._. These_DT data_NNS may_MD be_VB useful_JJ in_IN
        understanding_VBG the_DT patient_NN groups_NNS at_IN high_JJ risk_NN for_IN
        influenza-related_JJ complications_NNS and_CC assisting_VBG the_DT
        cost-benefit_JJ evaluation_NN of_IN a_DT more_RBR universal_JJ influenza_NN
        immunization_NN program_NN for_IN these_DT patients_NNS ._.
        Both_DT chronic_JJ and_CC acute_JJ manifestations_NNS of_IN comorbid_NN
        illness_NN were_VBD strong_JJ ,_, independent_JJ predictors_NNS of_IN
        influenza_NN /_NN ILI-related_NNP complications_NNS and_CC hospitalizations_NNS ._.
        Additionally_RB ,_, health_NN care_NN costs_NNS in_IN the_DT three_CD months_NNS before_IN
        the_DT influenza_NN /_NN ILI_NNP episode_NN serve_VB as_IN a_DT surrogate_NN for_IN the_DT
        overall_JJ health_NN status_NN of_IN a_DT patient_NN and_CC could_MD reflect_VB the_DT
        severity_NN of_IN the_DT underlying_VBG diseases_NNS ._. We_PRP were_VBD unable_JJ to_TO
        evaluate_VB the_DT effect_NN of_IN HIV_NNP infection_NN ,_, chronic_JJ renal_JJ
        disease_NN ,_, and_CC immunosuppressive_JJ therapy_NN due_JJ to_TO small_JJ number_NN
        of_IN patients_NNS with_IN these_DT co-morbidities_JJ ._. These_DT groups_NNS of_IN
        patients_NNS are_VBP at_IN high_JJ risk_NN for_IN influenza_NN /_NN ILI-related_NNP
        complications_NNS and_CC health_NN care_NN costs_NNS ._. Therefore_RB ,_, our_PRP$
        estimates_NNS are_VBP most_RBS likely_JJ an_DT under_JJ representation_NN of_IN the_DT
        true_JJ burden_NN of_IN influenza_NN /_NN ILI_NNP ._.
        The_DT 21_CD -_: day_NN follow-up_JJ period_NN incorporated_VBD a_DT clinical_JJ
        expectation_NN that_IN the_DT vast_JJ majority_NN of_IN influenza_NN /_NN ILI-related_NNP
        complications_NNS would_MD occur_VB within_IN this_DT period_NN ,_, and_CC that_IN
        complications_NNS that_WDT extended_VBD beyond_IN 21_CD days_NNS would_MD usually_RB be_VB
        ascribable_JJ in_IN part_NN to_TO preexisting_VBG illness_NN ._. We_PRP chose_VBD the_DT
        21_CD -_: day_NN cutoff_NN as_IN a_DT rough-and-ready_JJ ,_, approximate_JJ partition_NN
        of_IN mulitfactorial_NN disease_NN burden_NN ._. More_JJR sophisticate_NN
        approaches_NNS are_VBP imaginable_JJ ,_, but_CC not_RB among_IN multiple_JJ causes_NNS ,_,
        which_WDT in_IN any_DT case_NN would_MD have_VB been_VBN impossible_JJ to_TO implement_VB
        at_IN the_DT level_NN of_IN insurance_NN claims_NNS analysis_NN ._.
        These_DT data_NNS reflect_VBP patterns_NNS of_IN care_NN for_IN influenza_NN /_NN ILI_NNP
        seen_VBN within_IN the_DT NEI_NNP health_NN care_NN system_NN ._. NEI_NNP beneficiaries_NNS
        who_WP sought_VBD medical_JJ care_NN outside_IN the_DT NEI_NNP system_NN would_MD not_RB be_VB
        captured_VBN in_IN the_DT claims_NNS data_NN and_CC are_VBP not_RB included_VBN in_IN this_DT
        analysis_NN ._. This_DT is_VBZ probably_RB a_DT relatively_RB small_JJ percentage_NN of_IN
        patients_NNS and_CC is_VBZ unlikely_JJ to_TO bias_NN the_DT results_NNS ._. More_RBR
        importantly_RB ,_, care_NN for_IN many_JJ respiratory_JJ conditions_NNS
        (_( especially_RB otitis_NNS media_NNS and_CC acute_JJ bronchitis_NNS )_) was_VBD captured_VBN
        in_IN this_DT study_NN only_RB as_IN a_DT complication_NN of_IN previously_RB
        recognized_VBN influenza_NN /_NN ILI_NNP ._. If_IN the_DT original_JJ illness_NN had_VBD been_VBN
        diagnosed_VBN only_RB as_IN one_CD of_IN these_DT conditions_NNS ,_, it_PRP would_MD never_RB
        have_VB entered_VBN into_IN the_DT study_NN ._. In_IN addition_NN ,_, we_PRP lack_VBP data_NNS on_IN
        patients_NNS who_WP did_VBD not_RB seek_VB medical_JJ care_NN for_IN influenza_NN /_NN ILI_NNP ._.
        Medications_NNP purchased_VBD outside_IN the_DT insurance_NN plan_NN (_( e_SYM ._. g_SYM ._.
        over-the-counter_JJ )_) are_VBP not_RB included_VBN in_IN the_DT database_NN ._. Thus_RB ,_,
        influenza_NN /_NN ILI-related_NNP costs_NNS we_PRP report_VBP are_VBP likely_JJ to_TO be_VB an_DT
        under_JJ estimate_NN of_IN the_DT true_JJ costs_NNS of_IN medical_JJ care_NN ,_, and_CC this_DT
        is_VBZ only_RB a_DT fraction_NN of_IN the_DT total_JJ societal_NN cost_NN ,_, which_WDT would_MD
        include_VB at_IN a_DT minimum_NN lost_VBD wages_NNS and_CC productivity_NN ._. NEI_NNP
        enrolls_NNS relatively_RB few_JJ persons_NNS over_IN the_DT age_NN of_IN 65_CD ,_, due_JJ to_TO
        the_DT availability_NN of_IN Medicare_NNP coverage_NN for_IN the_DT elderly_JJ ._. The_DT
        elderly_JJ in_IN NEI_NNP include_VBP those_DT who_WP are_VBP still_RB working_VBG or_CC who_WP
        formerly_RB worked_VBD for_IN the_DT state_NN or_CC federal_JJ government_NN and_CC
        therefore_RB are_VBP not_RB eligible_JJ for_IN Medicare_NNP ._.
        Approximately_RB 78_CD %_NN of_IN influenza_NN isolates_VBZ from_IN the_DT World_NNP
        Health_NNP Organization_NNP Collaborating_NNP Laboratories_NNPS were_VBD type_NN A_DT
        and_CC 22_CD %_NN were_VBD type_NN B_NNP during_IN the_DT 1996_CD -_: 1997_CD influenza_NN
        season_NN ._. Type_NNP A_DT influenza_NN is_VBZ thought_VBN to_TO cause_VB more_RBR severe_JJ
        illness_NN [_NN 17_CD 18_CD 19_CD ]_NN ._. Therefore_RB ,_, the_DT majority_NN of_IN
        influenza_NN /_NN ILI_NNP diagnoses_NNS captured_VBN in_IN the_DT NEI_NNP system_NN using_VBG
        ICD-_NNP 9_CD codes_NNS would_MD be_VB expected_VBN to_TO be_VB type_NN A_DT and_CC represent_VB a_DT
        higher_JJR proportion_NN of_IN true_JJ influenza_NN illness_NN than_IN ILI_NNP during_IN
        the_DT 1996_CD -_: 1997_CD influenza_NN season_NN ._.
        Antiviral_NNP use_NN was_VBD not_RB extensive_JJ ,_, and_CC the_DT current_JJ study_NN
        dates_NNS preceded_VBN the_DT introduction_NN of_IN zanamivir_NN and_CC
        oseltamivir_NN ._. We_PRP found_VBD some_DT indication_NN (_( although_IN not_RB
        statistically_RB significant_JJ )_) that_IN antiviral_JJ use_NN may_MD have_VB
        prevented_VBN hospitalizations_NNS (_( OR_NNP =_SYM 0_CD ._. 6_CD )_) ._. The_DT recent_JJ marketing_NN
        of_IN influenza_NN antivirals_NNS may_MD have_VB an_DT even_RB greater_JJR impact_NN on_IN
        the_DT predictors_NNS of_IN complications_NNS and_CC health_NN care_NN related_VBD
        costs_NNS of_IN influenza_NN ._.
        Strengths_NNP of_IN this_DT study_NN include_VBP the_DT large_JJ cohort_NN of_IN ILI_NNP
        and_CC influenza_NN cases_NNS (_( over_IN 6200_CD patients_NNS )_) and_CC the_DT diversity_NN
        of_IN the_DT risk_NN profiles_NNS for_IN influenza_NN /_NN ILI-related_NNP
        complications_NNS in_IN this_DT population_NN ._. These_DT data_NNS should_MD be_VB
        applicable_JJ to_TO other_JJ large_JJ health_NN maintenance_NN organizations_NNS
        and_CC would_MD be_VB useful_JJ for_IN evaluating_VBG the_DT burden_NN of_IN
        influenza_NN /_NN ILI_NNP in_IN these_DT populations_NNS ._.
      
      
        Conclusions_NNP
        Recent_JJ acute_JJ events_NNS foretell_NN complications_NNS of_IN influenza_NN ,_,
        as_IN does_VBZ underlying_VBG chronic_JJ illness_NN ._. Most_JJS costs_NNS in_IN the_DT three_CD
        weeks_NNS following_VBG onset_NN are_VBP for_IN influenza_NN /_NN ILI-related_NNP
        care_NN ._.
      
      
        Competing_VBG interests_NNS
        SC_NNP ,_, W-YH_NNP ,_, and_CC DR_NNP were_VBD employees_NNS of_IN Glaxo_NNP Wellcome_NNP (_( now_RB
        GlaxoSmithKline_NNP )_) ,_, the_DT manufacturer_NN of_IN zanamivir_NN ,_, at_IN the_DT
        time_NN this_DT study_NN was_VBD carried_VBN out_RP ._. DI_NNP ,_, AMW_NNP ,_, and_CC LW_NNP were_VBD
        employees_NNS of_IN lngenix_NN Pharmaceutical_NNP Services_NNPS ,_, which_WDT
        received_VBD a_DT research_NN contract_NN to_TO perform_VB this_DT study_NN from_IN
        Glaxo_NNP Wellcome_NNP ._.
      
    
  
